	Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies
	Boehringer backs education drive to improve bronchiectasis management
	Lilly and Boehringer biosimilar undercuts Lantus by 15% - pharmaphorum
	PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
	Boehringer Ingelheim selects new oncology drug candidate from Oxford Biotherapeutics collaboration
	Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States
	Boehringer Ingelheim Argentina Collaborates To Bring Digital Healthcare Solutions to Remote Communities
	Pharma gets social: what will Boehringer Ingelheim’s Syrum game achieve?